ALNOX Share Price | TME Pharma NV Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare TME Pharma NV with Similar Stocks

NFL Biosciences SAS GeNeuro SA (Switzerland)genOway SA

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

EUR 7 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.17

Return on Equity

457.60%

Price to Book

-6.85

Revenue and Profits:

Net Sales:

(Quarterly Results - )

Net Profit:

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

1.91%

6 Months

-8.9%

1 Year

-56.44%

2 Years

-92.27%

3 Years

-98.53%

4 Years

-99.72%

5 Years

-99.83%

TME Pharma NV for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.59%

EBIT Growth (5y)

-3.57%

EBIT to Interest (avg)

-4.05

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.98

Sales to Capital Employed (avg)

0.02

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-7.48

EV to EBIT

-1.63

EV to EBITDA

-1.63

EV to Capital Employed

-7.31

EV to Sales

7.31

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by TME Pharma NV"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 14.93% vs 55.63% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.20",
          "val2": "-5.50",
          "chgp": "5.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "1.50",
          "chgp": "-66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.70",
          "val2": "-6.70",
          "chgp": "14.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-5.20

-5.50

5.45%

Interest

0.50

1.50

-66.67%

Exceptional Items

0.00

Consolidate Net Profit

-5.70

-6.70

14.93%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 14.93% vs 55.63% in Dec 2023

All Annual Results

Company CV

About TME Pharma NV

TME Pharma NV

Pharmaceuticals & Biotechnology

NOXXON Pharma NV is a biotechnology company based in the Netherlands that focuses on cancer treatments. The Company's main product is the Spiegelmer platform. Spiegelmers are a variant of a drug class called aptamers, which are based on deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and are built on a backbone of mirror-image RNA or DNA - L-stereoisomers. The Company's lead candidate, NOX-A12, is under development as a combination therapy for a number of cancer indications using immuno-oncology approaches, such as immune checkpoint inhibition and current standards of care, such as chemotherapy and radiotherapy. The Company also develops NOX-E36, which is aimed at the treatment of complications arising from diabetic nephropathy.

Company Coordinates

Company Details

Max-Dohrn-Str. 8-10 , BERLIN None : 10589

Tel: 49 30 7262470

https://www.noxxon.com/

Registrar Details